Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to the latest research, the global Pembrolizumab market size was valued at USD 18644.34 million in 2022 and is expected to expand at a CAGR of 5.62% during the forecast period, reaching USD 25884.98 million by 2028.
Pembrolizumab is a therapeutic antibody that binds and blocks PD-1 located on lymphocytes. This receptor is usually responsible for preventing the immune system from attacking the body's own tissues. Keytruda® is the trade drug name of Pembrolizumab.
Since 2019, Pembrolizumab has been used by intravenous infusion to treat melanoma, metastatic non-small cell lung cancer (NSCLC) that is inoperable or metastatic in some cases, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin after platinumbased chemotherapy, it can be used as a second-line treatment for head and neck squamous cell carcinoma (HNSCC), and it can treat refractory classic Hodgkin lymphoma (CHL) in adults and children and recurrent locally advanced or metastatic esophageal squamous cell carcinoma.
Influence of COVID-19 Outbreak on Pembrolizumab Industry Development
The society has been significantly suffered from the outbreak of CIVD-19. Many industries are expected to be in trouble due to the decrease of demand and the shut down of factories. However, because Pembrolizumab is a medicine that can cure or comfort patients with cancer, the impact on the demand side will have some effects while the supply chain is seriously affected.
Pembrolizumab is a necessity to patients who desperately rely on it to continue their life. Although the likelihood of world economy stepping in recession is high, and those people may get into severe financial trouble, the government and charity will help them out and overall demand is not as seriously affected as the supply side.
The supply chain is an important part during sales. Without production, the entire sales process will collapse. However, the outbreak of COVID-19 forced government to declare an emergency and regulates enterprise to shut down the business and stay at home. General research, production and sales activity are temporarily stopped. According to Merck, they help only eligible patients living in the USA figure out what to do during this difficult time. Therefore, considering the effects of both demand and supply, we expect the market will still grow but not as quick as last year.
Strength
Increasing downstream demand.
Continuous improvement of production process.
Weakness
Only one company is produing the medicine and less than 20 authorzied distributors.
may limit the circulation of the drug.
Region Overview:
From 2023-2028, North America is estimated to witness robust growth prospects.
Company Overview:
Merck & Co., Inc. is one of the major players operating in the Pembrolizumab market, holding a share of 100% in 2020.
Merck Pharmaceuticals, founded in 1891, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. Merck provides health solutions through its prescription drugs, vaccines, biotherapy, animal health and consumer health products. The company has operations in the fields of pharmaceuticals, animal health and consumer health.
Segmentation Overview:
Among different product types, 100mg Injection segment is anticipated to contribute the largest market share in 2028.
Application Overview:
By application, the NSCLC segment occupied the biggest share from 2018 to 2022.
This report elaborates on the market size, market characteristics, and market growth of the Pembrolizumab industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Pembrolizumab. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Pembrolizumab Market Report Include:
Market Size Estimates: Pembrolizumab market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Pembrolizumab market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Pembrolizumab market
Segment Market Analysis: Pembrolizumab market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Pembrolizumab market situations and prospects in major and top regions and countries
Pembrolizumab Market
Pembrolizumab Industry Chain: Pembrolizumab market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Pembrolizumab Industry News, Policies by regions
Pembrolizumab Industry Porters Five Forces Analysis
Key players in the global Pembrolizumab market are covered in Chapter 2:
Merck & Co., Inc.
In Chapter 6 and Chapter 9, on the basis of types, the Pembrolizumab market from 2018 to 2028 is primarily split into:
50mg Injection
100mg Injection
In Chapter 7 and Chapter 10, on the basis of applications, the Pembrolizumab market from 2018 to 2028 covers:
Melanoma
Non-Small Cell Lung Cancer NSCLC
Head and Neck Squamous Cell Carcinoma HNSCC
Other
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Pembrolizumab market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Pembrolizumab industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Pembrolizumab market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Pembrolizumab industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Pembrolizumab market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Pembrolizumab market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Pembrolizumab market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Pembrolizumab is a therapeutic antibody that binds and blocks PD-1 located on lymphocytes. This receptor is usually responsible for preventing the immune system from attacking the body's own tissues. Keytruda® is the trade drug name of Pembrolizumab.
Since 2019, Pembrolizumab has been used by intravenous infusion to treat melanoma, metastatic non-small cell lung cancer (NSCLC) that is inoperable or metastatic in some cases, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin after platinumbased chemotherapy, it can be used as a second-line treatment for head and neck squamous cell carcinoma (HNSCC), and it can treat refractory classic Hodgkin lymphoma (CHL) in adults and children and recurrent locally advanced or metastatic esophageal squamous cell carcinoma.
Influence of COVID-19 Outbreak on Pembrolizumab Industry Development
The society has been significantly suffered from the outbreak of CIVD-19. Many industries are expected to be in trouble due to the decrease of demand and the shut down of factories. However, because Pembrolizumab is a medicine that can cure or comfort patients with cancer, the impact on the demand side will have some effects while the supply chain is seriously affected.
Pembrolizumab is a necessity to patients who desperately rely on it to continue their life. Although the likelihood of world economy stepping in recession is high, and those people may get into severe financial trouble, the government and charity will help them out and overall demand is not as seriously affected as the supply side.
The supply chain is an important part during sales. Without production, the entire sales process will collapse. However, the outbreak of COVID-19 forced government to declare an emergency and regulates enterprise to shut down the business and stay at home. General research, production and sales activity are temporarily stopped. According to Merck, they help only eligible patients living in the USA figure out what to do during this difficult time. Therefore, considering the effects of both demand and supply, we expect the market will still grow but not as quick as last year.
Strength
Increasing downstream demand.
Continuous improvement of production process.
Weakness
Only one company is produing the medicine and less than 20 authorzied distributors.
may limit the circulation of the drug.
Region Overview:
From 2023-2028, North America is estimated to witness robust growth prospects.
Company Overview:
Merck & Co., Inc. is one of the major players operating in the Pembrolizumab market, holding a share of 100% in 2020.
Merck Pharmaceuticals, founded in 1891, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. Merck provides health solutions through its prescription drugs, vaccines, biotherapy, animal health and consumer health products. The company has operations in the fields of pharmaceuticals, animal health and consumer health.
Segmentation Overview:
Among different product types, 100mg Injection segment is anticipated to contribute the largest market share in 2028.
Application Overview:
By application, the NSCLC segment occupied the biggest share from 2018 to 2022.
This report elaborates on the market size, market characteristics, and market growth of the Pembrolizumab industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Pembrolizumab. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Pembrolizumab Market Report Include:
Market Size Estimates: Pembrolizumab market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Pembrolizumab market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Pembrolizumab market
Segment Market Analysis: Pembrolizumab market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Pembrolizumab market situations and prospects in major and top regions and countries
Pembrolizumab Market
Competitive Landscape
and Major Players: Analysis of 10-15 leading market players, sales, price, revenue, gross, gross margin, product/service profile and recent development/updates, etc.Pembrolizumab Industry Chain: Pembrolizumab market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Pembrolizumab Industry News, Policies by regions
Pembrolizumab Industry Porters Five Forces Analysis
Key players in the global Pembrolizumab market are covered in Chapter 2:
Merck & Co., Inc.
In Chapter 6 and Chapter 9, on the basis of types, the Pembrolizumab market from 2018 to 2028 is primarily split into:
50mg Injection
100mg Injection
In Chapter 7 and Chapter 10, on the basis of applications, the Pembrolizumab market from 2018 to 2028 covers:
Melanoma
Non-Small Cell Lung Cancer NSCLC
Head and Neck Squamous Cell Carcinoma HNSCC
Other
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Pembrolizumab market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Pembrolizumab industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Pembrolizumab market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Pembrolizumab industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Pembrolizumab market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Pembrolizumab market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Pembrolizumab market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
